Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Stockwatch: Allos - Anatomy of an Acquisition

This article was originally published in Scrip

Executive Summary

Spectrum Pharmaceuticals managed to mute the negative reaction to its two phase III failures for their bladder cancer therapy, apaziquone just before the weekend by announcing a $206 million acquisition of Allos Therapeutics (, 06 April 2012). Allos was previously the subject of a $260 million tug of war between AMAG and the Allos shareholders. That transaction was dissolved in four months, after counter-offers from, and lawsuits by, the Allos shareholders (, 21 November 2011). Paradoxically, a lower offer than that of AMAG seems to have already been accepted by about a quarter of Allos' shareholders on the basis of Spectrum's better stewardship of oncology assets.

You may also be interested in...

Stockwatch: The Post-Pandemic Dynamics Of Coronavirus Vaccines

Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.

Stockwatch: The Lexicon Of Biotech Survival

Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.

Stockwatch: Pandemic Cuts Deep Into Early Commercial Biotech

Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts